Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupIndolent LymphomasradiotherapyDiseaseNHL, B-Cell Type, Follicular Grade I-IIIaSubgroupICD10C82.9MeSHSequenceChemotherapyChemo-substanceCyclophosphamidePrednisoloneRituximabVincristineChemo-substanceCyclophosphamidePrednisoloneRituximabVincristineChemo-substanceCyclophosphamidePrednisoloneRituximabVincristineChemo-substanceCyclophosphamidePrednisoloneRituximabVincristineNo. Substances4 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDimetindenGranisetronMesnaParacetamolSupportive substanceBalanced Crystalloid SolutionDimetindenGranisetronMesnaParacetamolSupportive substanceBalanced Crystalloid SolutionDimetindenGranisetronMesnaParacetamolSupportive substanceBalanced Crystalloid SolutionDimetindenGranisetronMesnaParacetamolNo. Substances5Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksEmetogenicity (MASCC/ESMO)Febrile NeutropeniaHepatotoxicityInfectionsMucositisNeuropathyNeutropenia only studiesPublicationAuthorMacManus MDiseaseFoll. Lymphom, Grad I-IIIa, Stadium I-II, ErstlinientherapieOriginPeter MacCallum Cancer Centre, Melbourne, Australia, TROG 99.03Protocols in Revision 1 protocol foundProtocols under revision.R-CVP - Rituximab 375 / Cyclophosphamide 1000 / Vincristine 2 / Prednisolone 50 / Radiation, follicular lymphoma grade I-IIIa (PID1575 V1.0)
